These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 16798283

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome.
    Ben Ayed B, Dammak dit Mlik S, Ben Arab H, Trabelssi H, Chahtour H, Mathlouthi N, Dhuib M, Kassis M, Saiidane D, Trabelssi K, Guermazi M.
    Tunis Med; 2009 Jan; 87(1):43-9. PubMed ID: 19522426
    [Abstract] [Full Text] [Related]

  • 23. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
    [Abstract] [Full Text] [Related]

  • 24. Insulin resistance and the long-term consequences of polycystic ovary syndrome.
    Bhathena RK.
    J Obstet Gynaecol; 2011 Jun; 31(2):105-10. PubMed ID: 21281021
    [Abstract] [Full Text] [Related]

  • 25. Drug treatments for polycystic ovary syndrome.
    Radosh L.
    Am Fam Physician; 2009 Apr 15; 79(8):671-6. PubMed ID: 19405411
    [Abstract] [Full Text] [Related]

  • 26. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
    Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY, Zhang SH.
    Clin Endocrinol (Oxf); 2011 Mar 15; 74(3):332-9. PubMed ID: 21050251
    [Abstract] [Full Text] [Related]

  • 27. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
    Svendsen PF, Nilas L, Nørgaard K, Madsbad S.
    Ugeskr Laeger; 2005 Aug 22; 167(34):3147-51. PubMed ID: 16117910
    [Abstract] [Full Text] [Related]

  • 28. Insulin-sensitising agents in polycystic-ovary syndrome.
    Sattar N, Hopkinson ZE, Greer IA.
    Lancet; 1998 Jan 31; 351(9099):305-7. PubMed ID: 9652605
    [No Abstract] [Full Text] [Related]

  • 29. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
    Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS.
    Diabetes; 2008 Jun 31; 57(6):1501-7. PubMed ID: 18375437
    [Abstract] [Full Text] [Related]

  • 30. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Front Horm Res; 2013 Jun 31; 40():83-102. PubMed ID: 24002407
    [Abstract] [Full Text] [Related]

  • 31. Metformin in polycystic ovary syndrome.
    Fisken RA.
    N Engl J Med; 2008 Apr 24; 358(17):1866-7; author reply 1868. PubMed ID: 18437727
    [No Abstract] [Full Text] [Related]

  • 32. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Expert Opin Ther Targets; 2009 Oct 24; 13(10):1205-26. PubMed ID: 19650762
    [Abstract] [Full Text] [Related]

  • 33. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
    Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK.
    Fertil Steril; 2011 Jan 24; 95(1):203-9. PubMed ID: 20684955
    [Abstract] [Full Text] [Related]

  • 34. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
    Nawrocka J, Starczewski A.
    Gynecol Endocrinol; 2007 Apr 24; 23(4):231-7. PubMed ID: 17505944
    [Abstract] [Full Text] [Related]

  • 35. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance.
    Topcu S, Tok D, Caliskan M, Ozcimen EE, Gullu H, Uckuyu A, Erdogan D, Zeyneloglu H, Muderrisoglu H.
    Clin Endocrinol (Oxf); 2006 Jul 24; 65(1):75-80. PubMed ID: 16817823
    [Abstract] [Full Text] [Related]

  • 36. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome.
    Practice Committee of the American Society for Reproductive Medicine.
    Fertil Steril; 2004 Sep 24; 82 Suppl 1():S181-3. PubMed ID: 15363722
    [No Abstract] [Full Text] [Related]

  • 37. Metformin and polycystic ovary syndrome.
    Lebinger TG.
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr 24; 14(2):132-40. PubMed ID: 17940431
    [Abstract] [Full Text] [Related]

  • 38. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A, Amato MC, Giordano C.
    Nutr Metab Cardiovasc Dis; 2008 Sep 24; 18(7):511-8. PubMed ID: 18657405
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness of insulin sensitizing drugs for polycystic ovary syndrome.
    Julson H.
    Am Fam Physician; 2007 Nov 01; 76(9):1308-9. PubMed ID: 18019873
    [No Abstract] [Full Text] [Related]

  • 40. Metformin in polycystic ovary syndrome.
    Mascitelli L, Pezzetta F, Goldstein MR.
    N Engl J Med; 2008 Apr 24; 358(17):1867-8; author reply 1868. PubMed ID: 18437729
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.